Relapsed and refractory classical Hodgkin lymphoma

What changed: Relapsed and refractory classical Hodgkin lymphoma

Cancer page →

Every dated change on the records linked to Relapsed and refractory classical Hodgkin lymphoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Approval1Regulatory1Trial result3Milestone6This record1

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-18This recordRelapsed and refractory classical Hodgkin lymphoma
Facts on this page last checked
When this page itself was last checked or edited.

2021 · 1

2021MilestoneKEYNOTE-204
KEYNOTE-204: pembrolizumab beats brentuximab vedotin in relapsed disease
A milestone in how this cancer is treated.

2020 · 1

2020Trial resultKEYNOTE-204
KEYNOTE-204 reported
PFS 13.

2017 · 1

2017MilestonePembrolizumab
Pembrolizumab approved after KEYNOTE-087
A milestone in how this cancer is treated.

2016 · 2

2015 · 2

August 2011 · 1

2011-08-19RegulatoryBrentuximab vedotin
Brentuximab vedotin: approval (US)
Accelerated approval, relapsed Hodgkin lymphoma and systemic ALCL

2011 · 2

1993 · 1

1993MilestoneAutologous stem cell transplant (high-dose therapy)
Randomised trial confirms autologous transplantation improves outcomes in relapsed Hodgkin lymphoma
A milestone in how this cancer is treated.